19 July 2022: Articles
Infection Associated with COVID-19: A Case Series and Literature Review
Challenging differential diagnosis, Management of emergency care, Patient complains / malpractice, Rare disease, Adverse events of drug therapy, Educational Purpose (only if useful for a systematic review or synthesis)
Kazuhiro Ishikawa A* , Tomoaki Nakamura B , Fujimi Kawai F , Yuki Uehara D , Nobuyoshi Mori ADOI: 10.12659/AJCR.936889
Am J Case Rep 2022; 23:e936889
Table 5. List of retrospective cohort studies on Stenotrophomonas maltophilia secondary infection to COVID-19.
| No | Study | Published year/Country | Ward | number | Site of infection or isolation | Specimen | Mortality of respiratory infection | Top 5 pathogen | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Li J []18 | 2020/China | ICU | *102/**110 *all patients developing secondary bacterial infection ** lung infection | Respiratory infection | Sputum endotracheal aspiration, BAL | *49%*all patients developing secondary bacterial infection | 42.7%, 30.9%, 9.1%, 6.4%, 3.6% | |
| 2 | Foschi C []27 | 2021/Italy | ICU | 178/**230 *patients developing respiratory infection ** number of lower respiratory samples | Respiratory infection | BAL, bronchial aspiration | N/A | 14.7%, 6.9%, 3.4%, 3.4%, 3.4% | |
| 3 | Yang S []9 | 2021/China | ICU | *13/**96 *critical group patients *number of specimens (BAL, sputum) | Respiratory infection | Sputum, BAL in the critical group | N/A | 18.8%, 15.6%, 7.3%, 6.3%, 5.2%,* pathogens detected only in the critical group | |
| 4 | Garcia-Vidal C []28 | 2021/Spain | ICU, non-ICU | *11(VAP), *4(HAP) *patients developing infection | VAP, HAP | sputum, BAL | N/A | VAP 36.4%, 27.3%, 18.2%, 9%HAP 25%, 25%, 25%, 25% | |
| 5 | Moretti M []29 | 2021/Belgium | ICU | *21* VAP patients | VAP | Endotracheal aspiration BAL | 52.4% (VAP) | 25.93%, 18.52%, 11.11%, spp. 11.11%, 7.41%,7 3.70% | |
| 6 | Puzniak L []30 | 2021/USA | N/A | *5012*all specimens | isolation | Urinary, respiratory, blood, skin/wound, intra-abdominal and other specimen | N/A | 31.8%, 13.7%, spp. 7.1%, 6.5%, 1.9%, 0.8%,only SARS-CoV-2 positive group | |
| 7 | Baiou A []31 | 2021/Qatar | ICU | *78/**98*patients who has isolation of multi-drug-resistant gram-negative bacteria (MDR GNB) **the number of MDR GNB specimens | Respiratory infection, bacteremia, UTI | Respiratory tract, blood, urine | 15.4% (all-cause mortality by 28 day) | 24.25%, 23.24%, 18.18%, 12.12%, 12. 12% | |
| 8 | Bardi T []32 | 2021/Spain | ICU | *57/**30(VAP 21, HAP 9*patients developing nosocomial infection during ICU**number of episodes | VAP, HAP | Tracheal aspiration | *36%/*37%*all-cause mortality by 28 day** death within all-cause mortality by refractory respiratory failure | VAP 38%,MRSA 24%, 9%, 5%, 5%HAP 33%,MRSA 21%, 9%,MSSA 9%, 9% | |
| 9 | Zhang D []33 | 2021/China | N/A | 23*number of sputum, BAL specimens | Respiratory infection | Sputum, BAL | NA | 26.1%, 21.7%, 13.0%,,, complex8.7% | |
| 10 | Signorini L []10 | 2021/Italy | ICU | *53/**75 *patient developing super infection **VAP infection | VAP, HAP | BAL | 49.1% (28 day mortality of superinfection) | 34.7%, 18.7% | |
| 11 | Martinez-Guerra BA []34 | 2021/Mexico | ICU, non-ICU | *69/**56* number of specimens of VAP, HAP**number of VAP, HAP episode | VAP, HAP | N/A | N/A | complex42.0%, 14.5%, spp. 13.0%, 13.0%, 8.7% | |
| 12 | Sang L []35 | 2021/China | ICU | 165/**935*number of positive culture patients**number of lower respiratory samples | HAP, VAP | Lower respiratory tract aspiration | 51.6% at positive culture group (28 days ICU mortality rate) | 24.6%, 24.3%, 11.1%, 5.7%, 4.2% | |
| 13 | Luyt C-E []36 | 2020/France | ICU | *43 number of VAP patients | VAP | BAL | 9% Died on VAP treatment | 37%, 26%, 7%, spp. 7%, spp. 7%,MRSA 5% 5%, 5% | |
| HAP – hospital-acquired pneumoniae; VAP – ventilator-associated pneumonia; MOF – multiple organ failure; ARDS – acute respiratory distress syndrome; CAPA – COVID-19 associated pulmonary aspergillosis; Af – atrial filtration; HTN – hypertension; CAD – coronary artery disease; DM – diabetes; ESRD – end stage renal disease; TAC – tacrolimus; MMF – mycophenolate mofetil; PSL – prednisolone; BMI – body mass index; COPD – chronic obstructive pulmonary disease; TB – tuberculosis; SLE – systemic lupus erythematous; RA – rheumatic arthritis; IP – interstitial pneumonia; LC – liver cirrhosis; CABG – coronary artery bypass graft; ICU – Intensive Care Unit; ECMO – extracorporeal membrane oxygenation; N/A – not applicable; HCQ – hydroxychloroquine; AZM – azithromycin; mPSL – methylprednisolone; RDV – remdesivir; DEXA – dexamethasone; QID – quater in die; BARI – baricitinib; CFPM – cefepime; MEPM – meropenem; PIPC/TAZ – piperacillin/tazobactam; VCM – vancomycin; CAZ – ceftazidime; TOB – tobramycin; TMPSMX – trimethoprim/sulfamethoxazole; LVFX – levofloxacin; MINO – minocycline; AKI – acute kidney injury; FOM – fosfomycin; – – – . – – UTI – urinary tract infection; BAL – bronchoalveolar lavage; – – – – – – – – – – – – methicillin-resistant – – – . | |||||||||